QIAGEN N.V.（凯杰公司） - Global Leader in Sample to Insight Molecular Diagnostics Solutions

Company Profile (Updated April 2026)

QIAGEN N.V. is a global leader in Sample to Insight solutions that enAble customers to extract and analyze molecular information from biological samples containing the building blocks of life. Founded in 1984 and headquartered in Venlo, the Netherlands with major operations in Hilden, Germany, QIAGEN has established itself as the world's leADINg provider of innovative sample and assay technologies for molecular diagnostics, life Sciences research, and applied testing.

The company serves more than 500,000 customers worldwide across academia, pharmaceutical R&D, industrial applications (including forensics), and clinical healthcare. With approximately 5,700 employees across more than 35 locations globally, QIAGEN generates nearly 90% of its revenue from consumables, with the balance from instrumentation and related services. The Americas account for approximately 52% of revenue, followed by EMEA (33%) and Asia-Pacific (15%).

Corporate History & Leadership

Founded: 1984
   Legal Headquarters: Venlo, the Netherlands (QIAGEN N.V. is a Netherlands-based holding company)
   Major Operations: Hilden, Germany; Germantown, Maryland, USA
   CEO & Managing Director: Thierry Bernard (appointed 2019; announced departure in November 2025, successor to be appointed)
   CFO & Managing Director: Roland Sackers
   Company Type: Public Company (NYSE: QGEN; Frankfurt Prime Standard: QIA)
   Market Cap: ~$10.1 billion (as of February 2026)
   Employees: ~5,700
   FY2025 Net Sales: $2.09 billion (+6% actual rates; +5% CER)
   FY2025 Adjusted Diluted EPS: $2.38 ($2.40 CER)
   FY2025 Diluted EPS (GAAP): $1.94
   Website: www.qiagen.com

Under Thierry Bernard's leadership since 2019, QIAGEN navigated the 2020 Thermo Fisher acquisition attempt ($12.5 billion, collapsed after shareholder rejection), advanced digital transformation, and positioned the company for solid profitable growth toward 2028 targets.

Business Portfolio & Technology Platforms

Sample Technologies

QIAGEN's Foundation—solutions to collect, stabilize, isolate, and purify DNA, RNA, and proteins from any biological sample (blood, tissue, etc.). These technologies ensure reproducible, standardized processing with the highest quality before analysis.

- Manual and Automated Purification Kits: For genotyping, gene expression, viral and bacterial analysis

- Silica Membranes and Magnetic Bead Technologies: Core purification technologies

- Parse Biosciences (Acquired 2025): Single-cell analysis technology expanding QIAGEN's sample portfolio into high-throughput single-cell RNA sequencing

Assay Technologies

Reagents and testing solutions that make specific target biomolecules visible for detection and analysis, including pre-configured closed assays.

- QuantiFERON-TB Gold Plus: Market-leading interferon-gamma release assay for latent tuberculosis (TB) infection testing; fifth generation in development for 2026 launch with 75% more patients per hour and 25% faster results

- HPV Testing: One of the largest and most rapidly expanding molecular diagnostics segments in women's health

- Immune Response Assays: Post-transplant testing and viral load monitoring

- Oncology and Sexual/Reproductive Health: Prenatal testing, sexually transmitted disease detection

- Research PCR Consumables: Quantitative PCR, reverse transcription, and combination kits for gene expression, genotyping, and gene regulation

- Human ID/Forensics: Short tandem repeat assays for human identification and food contamination testing

QIAGEN Digital Insights (QDI) / Bioinformatics

Software-as-a-service and bioinformatics solutions for interpreting complex molecular data to deliver actionable insights.

- Genoox (Acquired 2025): Strengthens QDI's capabilities in genomic variant interpretation and clinical decision support

- Single-Cell Data Integration: QDI plans to integrate Parse Biosciences single-cell datasets to develop predictive modeling and target discovery tools for pharmaceutical partners in oncology, neurology, and immunology

Automation Solutions

Integrated instruments and platforms that streamline workflows from sample to result.

- QIAsymphony: Modular automation platform covering entire workflow from sample to result

- QIAstat-Dx: Syndromic testing platform for one-step molecular analysis of hard-to-diagnose syndromes; surpassed 5,200 global installations by end of 2025; expanded in April 2026 with BCID GPF Plus AMR Panel for bloodstream infection and sepsis detection

- NeuMoDx (Discontinued 2025): Automated molecular testing platform; discontinued with approximately $20 million headwind impact on FY2025 results, alongside Dialunox

Growth Pillars & Financial Performance

QIAGEN focuses on five strategic growth pillars that drive sustainable expansion:

- 2025 Combined Growth Pillar Sales: $1.49 billion CER (+8% CER growth)

- 2026 Growth Pillar Outlook: ~$1.64 billion CER (~+9% CER growth)

- 2028 Target: Net sales CER CAGR greater than or equal to 31% (2024-2028); at least $2 billion net sales CER from growth pillars in 2028

Fiscal Year 2025 (Ended December 31, 2025)

- Total Net Sales: $2.09 billion (+6% actual rates; +5% CER), at high end of 4-5% CER outlook

- Q4 2025 Net Sales: $540.4 million (+4% actual; +1% CER), exceeding outlook for steady results

- Adjusted Operating Income Margin: 29.5% (+80 basis points vs. 2024), despite 80 bps headwind from tariffs and 40 bps from currency

- Adjusted Diluted EPS: $2.38 ($2.40 CER), ahead of $2.38 CER outlook and $0.12 ahead of initial 2025 outlook

- GAAP Diluted EPS: $1.94

- Operating Cash Flow: $654 million (absorbing $54 million cash restructuring payments for efficiency program)

- Capital Expenditures: $201 million (reflecting investments in new ERP system S/4HANA)

- Capital Deployment: More than $1.1 billion returned to shareholders through share repurchases and dividends

- Cash Position: Approximately $839 million

Q4 2025 Performance

- Net Sales: $540.4 million

- GAAP Gross Profit: $325.3 million (60.2% gross margin)

- Adjusted Gross Profit: $355.5 million (65.8% adjusted gross margin)

- GAAP Operating Income: $99.5 million

- Adjusted Operating Income: $154.4 million

- GAAP Diluted EPS: $0.49

- Adjusted Diluted EPS: $0.62 ($0.62 CER), ahead of ~$0.60 CER outlook

Geographic Revenue Distribution

- Americas: ~52% of total revenue (largest market)

- EMEA (Europe, Middle East, Africa): ~33% of total revenue

- Asia-Pacific: ~15% of total revenue

Recent Strategic Developments (2024-2026)

CEO Transition (November 2025): Thierry Bernard announced he will step down after a successor is appointed and will not stand for re-election to the Supervisory Board at the 2026 Annual General Meeting. The Supervisory Board and outgoing CEO agreed on transition timing. As of April 2026, no successor has been publicly named.

Strategic Acquisitions:

- Parse Biosciences ($225M upfront + up to $55M milestones, December 2025): Seattle-based single-cell analysis company; expands QIAGEN's Sample Technologies portfolio into single-cell RNA sequencing

- Genoox (2025): Strengthens QDI bioinformatics and genomic variant interpretation capabilities

Capital Allocation:

- January 2026: Completed $500 million synthetic share repurchase

- Shareholder Returns: More than $1.1 billion returned to shareholders to date, ahead of schedule

Product Innovation:

- QIAstat-Dx BCID GPF Plus AMR Panel (April 2026): New bloodstream infection panel detecting 20 Gram-positive bacterial and fungal pathogen targets plus 10 AMR genes from positive blood cultures; runs on QIAstat-Dx platform with 5,200+ global installations; showcased at ESCMID Global 2026 Congress in Munich; marks QIAGEN's entry into sepsis and bloodstream infection diagnostics following December 2025 regulatory submissions

- QuantiFERON Fifth Generation: In development for 2026 launch; partner Diasorin's LIAISON QuantiFERON-TB Gold Plus II assay launched in Europe 2025, US launch planned early 2026—enables 75% more patients per hour and 25% faster results

- AI in TB Diagnostics: Investigating AI to facilitate clinical decision making for latent TB infection progression risk assessment

Governance:

- Mark Stevenson joined Supervisory Board (January 2026): Former Executive Vice President and COO of Thermo Fisher; Operating Partner at Fivespan Partners

- Ross Levine stepped down (January 2026): After serving since 2016; continues as Chair of QIAGEN Scientific Advisory Board

2026 Outlook & Strategic Vision

FY2026 Guidance:

- Net Sales Growth: At least 5% CER from 2025

- Q1 2026 Outlook: Net sales of approximately $490 million CER (down about 4% CER), reflecting continued headwinds from NeuMoDx/Dialunox discontinuation and currency effects

- Growth Pillars: Expected to contribute about $1.64 billion CER (~+9% CER growth)

- Adjusted Diluted EPS: At least $2.50 CER (vs. $2.38 in 2025)

- Adjusted Operating Income Margin: Continuous solid operational margin expansion driven by operational leverage

- Growth Rhythm: About 3% growth in the first half of 2026, accelerating to 7-8% in the second half as headwinds ease

Strategic Priorities:

1. Drive Sales Growth Through Pillars: Launch new platforms and expand menu to drive recurring revenues

2. Leverage Portfolio in High-Value Areas: Increase focus on applications offering dynamic growth

3. Deliver Value from Bolt-On Acquisitions: Accelerate Parse and Genoox integration; consider additional opportunities

4. Continue Disciplined Capital Allocation: Invest to support future growth while increasing shareholder returns

2028 Targets:

- Net sales CER CAGR (2024-2028): greater than or equal to 31%

- Adjusted operating income margin CER (2028): Continued expansion

- Net sales CER from growth pillars in 2028: greater than or equal to $2 billion

Contact Information

Global Headquarters

Company: QIAGEN N.V.
   Address: Venlo, the Netherlands
   German Operations: QIAGEN GmbH, Hilden, Germany
   US Operations: QIAGEN Inc., Germantown, Maryland, USA
   Phone: +31 77 320 8400
   Website: www.qiagen.com
   Investor Relations: investors.qiagen.com

Key Personnel

CEO & Managing Director: Thierry Bernard
   CFO & Managing Director: Roland Sackers
   Supervisory Board Chair: Stephen H. Rusckowski
   Supervisory Board Member (joined 2026): Mark Stevenson

Keywords: QIAGEN,凯杰,Sample to Insight,molecular diagnostics,sample technologies,assay technologies,QuantiFERON,QuantiFERON-TB Gold Plus,HPV testing,NGS,next-generation sequencing,Parse Biosciences,Genoox,QDI,QIAGEN Digital Insights,Thierry Bernard,Roland Sackers,Venlo,Netherlands,Hilden,Germany,NYSE QGEN,QIA,Frankfurt,life sciences,bioinformatics,single-cell analysis,automation,QIAsymphony,QIAstat-Dx,QIAstat-Dx BCID,BCID GPF Plus AMR Panel,bloodstream infection,sepsis,AMR,antimicrobial resistance,ESCMID 2026,$2.09 billion revenue,$2.38 adjusted EPS,$2.50 CER EPS 2026,growth pillars,$1.49 billion CER,$1.64 billion CER 2026,5,700 employees,500,000 customers,NeuMoDx,Dialunox,$839 million cash,Q1 2026 $490M,5,200 installations